(Q42225912)

English

Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial

scientific article published on 30 July 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

0 references

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

4

object named as

C N Hayes

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

author name string

S Yokoyama

1

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

S Takahashi

2

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Y Kawakami

3

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

H Kohno

5

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

H Kohno

6

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

K Tsuji

7

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Y Aisaka

8

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

S Kira

9

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

K Yamashina

10

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

M Nonaka

11

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

T Moriya

12

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

M Kitamoto

13

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

S Aimitsu

14

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

T Nakanishi

15

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

H Kawakami

16

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

K Chayama

17

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

publication date

30 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

348-356

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Global epidemiology of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Response-guided telaprevir combination treatment for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Vitamin D: modulator of the immune system.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

25-Hydroxyvitamin D3 suppresses hepatitis C virus production

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Vitamin D and calcium deficits predispose for multiple chronic diseases

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

D-livering the message: the importance of vitamin D status in chronic liver disease

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12146

21 January 2018

Identifiers

10.1111/JVH.12146

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42225912&oldid=1937076776"